Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes.
D000328:Adult; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D000078404:Epidermal Cells; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D015603:Keratinocytes / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D009924:Organ Culture Techniques; D000077205:Pioglitazone; D011565:Psoriasis / Q000503:physiopathology; D000077154:Rosiglitazone; D015398:Signal Transduction / Q000187:drug effects; D045162:Thiazolidinediones / Q000494:pharmacology*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1; D000077205:Pioglitazone